Arcellx inc ACLX.US 總覽分析

美股醫療保健
(ACLX 無簡報檔)

ACLX 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低,若以價值投資為目標且有長期投資部位,需要嚴格執行自己的出場計畫來減持部位

ACLX 近期報酬表現

3.39%

Arcellx inc

4.57%

同產業平均

3.26%

S&P500

與 ACLX 同產業的標的表現

  • APGE Apogee therapeutics inc
    價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分
    查看更多

ACLX 公司資訊

Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

ACLX 股價